The United States market is experiencing a slight rebound, with major indices like the Dow Jones and S&P 500 inching upwards after recent sell-offs, while bond yields retreat from their highs. In this environment of fluctuating market sentiment and economic uncertainty, identifying high growth tech stocks requires careful consideration of their potential to innovate and adapt within the dynamic landscape.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 26.38% | 39.09% | ★★★★★★ |
| Ardelyx | 20.78% | 59.46% | ★★★★★★ |
| Travere Therapeutics | 26.41% | 64.47% | ★★★★★★ |
| Blueprint Medicines | 21.36% | 61.45% | ★★★★★★ |
| TG Therapeutics | 26.46% | 38.75% | ★★★★★★ |
| Alnylam Pharmaceuticals | 23.65% | 61.11% | ★★★★★★ |
| AVITA Medical | 27.28% | 60.66% | ★★★★★★ |
| Alkami Technology | 20.54% | 76.67% | ★★★★★★ |
| Ascendis Pharma | 35.16% | 60.26% | ★★★★★★ |
| Lumentum Holdings | 21.59% | 110.32% | ★★★★★★ |
Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Bitdeer Technologies Group (NasdaqCM:BTDR)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Bitdeer Technologies Group is a technology company focused on blockchain and computing, with a market cap of approximately $2.90 billion.
Operations: The company generates revenue primarily from data processing services, totaling $300.40 million.
Despite recent volatility, Bitdeer Technologies Group's trajectory in the high-growth tech sector is marked by notable developments and strategic innovations. With a reported annual revenue growth of 52.1% and an anticipated shift to profitability, reflecting a forecasted earnings growth of 65.83% per year, the company is aligning with market expectations for substantial financial improvement. Recent advancements include the successful testing of their SEAL03 Bitcoin mining chip, demonstrating significant power efficiency—a critical factor in sustaining long-term growth in cryptocurrency mining technology. Moreover, their active engagement in R&D with investments tailored towards next-generation technologies underlines a robust strategy to maintain competitive advantage within this rapidly evolving industry.
Capricor Therapeutics (NasdaqCM:CAPR)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy and other diseases with unmet medical needs in the United States, with a market capitalization of $503.24 million.
Operations: Capricor Therapeutics focuses on creating innovative cell and exosome-based therapies for Duchenne muscular dystrophy and other diseases lacking effective treatments. The company is in the clinical-stage of development, indicating that its revenue streams are not yet established through product sales.
Capricor Therapeutics has been navigating a challenging landscape with significant net losses reported in recent quarters, including a substantial increase to USD 24.39 million in Q1 2025 from USD 9.79 million the previous year. Despite these financial setbacks, the company is making promising advances in biotechnology; their lead asset, deramiocel, for treating Duchenne muscular dystrophy cardiomyopathy, is under FDA review with potential approval by August 2025. This treatment has shown efficacy in slowing disease progression by 52% compared to external controls during trials. These developments could position Capricor at the forefront of regenerative medicine for cardiac conditions if they manage to stabilize finances and advance their clinical outcomes.
- Unlock comprehensive insights into our analysis of Capricor Therapeutics stock in this health report.
Understand Capricor Therapeutics' track record by examining our Past report.
Neurocrine Biosciences (NasdaqGS:NBIX)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Neurocrine Biosciences, Inc. is engaged in the discovery, development, and marketing of pharmaceuticals targeting neurological, neuroendocrine, and neuropsychiatric disorders globally with a market cap of $12.17 billion.
Operations: The company focuses on the research, development, and commercialization of pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders, generating $2.41 billion in revenue.
Neurocrine Biosciences has recently demonstrated a strategic focus on expanding its product portfolio, as evidenced by multiple successful Phase 3 studies and subsequent FDA approvals. The company's robust pipeline is highlighted by CRENESSITY™ for congenital adrenal hyperplasia and INGREZZA® for movement disorders, both showing promising clinical outcomes that could enhance patient quality of life. Financially, Neurocrine closed several Shelf Registrations totaling over $1 billion in 2025 alone, reflecting strong market confidence and funding for future innovations. These developments underscore Neurocrine's commitment to addressing complex neurological and endocrine disorders through advanced therapeutics.
- Click here to discover the nuances of Neurocrine Biosciences with our detailed analytical health report.
Evaluate Neurocrine Biosciences' historical performance by accessing our past performance report.
Taking Advantage
- Unlock more gems! Our US High Growth Tech and AI Stocks screener has unearthed 232 more companies for you to explore.Click here to unveil our expertly curated list of 235 US High Growth Tech and AI Stocks.
- Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly.
- Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Bitdeer Technologies Group might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com